全文获取类型
收费全文 | 22011篇 |
免费 | 5996篇 |
国内免费 | 132篇 |
专业分类
耳鼻咽喉 | 631篇 |
儿科学 | 635篇 |
妇产科学 | 735篇 |
基础医学 | 464篇 |
口腔科学 | 2655篇 |
临床医学 | 4291篇 |
内科学 | 5231篇 |
皮肤病学 | 457篇 |
神经病学 | 1941篇 |
特种医学 | 1044篇 |
外科学 | 3907篇 |
综合类 | 89篇 |
现状与发展 | 12篇 |
预防医学 | 2798篇 |
眼科学 | 330篇 |
药学 | 267篇 |
中国医学 | 7篇 |
肿瘤学 | 2645篇 |
出版年
2024年 | 135篇 |
2023年 | 1098篇 |
2022年 | 358篇 |
2021年 | 641篇 |
2020年 | 1229篇 |
2019年 | 502篇 |
2018年 | 1344篇 |
2017年 | 1293篇 |
2016年 | 1518篇 |
2015年 | 1573篇 |
2014年 | 1986篇 |
2013年 | 2406篇 |
2012年 | 818篇 |
2011年 | 787篇 |
2010年 | 1391篇 |
2009年 | 1967篇 |
2008年 | 785篇 |
2007年 | 555篇 |
2006年 | 696篇 |
2005年 | 500篇 |
2004年 | 369篇 |
2003年 | 326篇 |
2002年 | 281篇 |
2001年 | 418篇 |
2000年 | 312篇 |
1999年 | 422篇 |
1998年 | 510篇 |
1997年 | 495篇 |
1996年 | 540篇 |
1995年 | 395篇 |
1994年 | 308篇 |
1993年 | 263篇 |
1992年 | 186篇 |
1991年 | 171篇 |
1990年 | 161篇 |
1989年 | 158篇 |
1988年 | 139篇 |
1987年 | 137篇 |
1986年 | 113篇 |
1985年 | 102篇 |
1984年 | 84篇 |
1983年 | 106篇 |
1982年 | 85篇 |
1981年 | 72篇 |
1980年 | 47篇 |
1979年 | 39篇 |
1978年 | 38篇 |
1977年 | 52篇 |
1976年 | 35篇 |
1975年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 156 毫秒
1.
2.
3.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
4.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
5.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
6.
7.
8.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
9.
10.